SCHEMBL14897368

SCHEMBL14897368

O=C(Nc1cccnc1)c1cnc2ccc(N3CCCC3)nn12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 3/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ NAMPT P43490 5/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ MAPT P10636 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ GFER P55789 1/20 0.45
▸ DRD2 P14416 2/20 0.44
▸ DRD4 P21917 2/20 0.44
▸ DRD3 P35462 1/20 0.43
▸ HIF1A Q16665 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ DNM1L O00429 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897625 0.91 SMN1; SMN2 (0.49) IRAK4ALDH1A1NAMPTSMN1; SMN2MAPT
SCHEMBL14896979 0.91 IRAK4 (0.49) IRAK4ALDH1A1NAMPTSMN1; SMN2RAB9A
SCHEMBL14897743 0.89 IRAK4 (0.45) IRAK4ALDH1A1NAMPTSMN1; SMN2LMNA
SCHEMBL14897324 0.88 IRAK4 (0.51) IRAK4ALDH1A1NAMPTSMN1; SMN2MAPT
SCHEMBL14897193 0.87 PTPN11 (0.47) IRAK4ALDH1A1NAMPTSMN1; SMN2LMNA
SCHEMBL14897106 0.86 NAMPT (0.43) IRAK4ALDH1A1NAMPTSMN1; SMN2LMNA
SCHEMBL14897490 0.86 IRAK4 (0.45) IRAK4ALDH1A1NAMPTSMN1; SMN2LMNA
SCHEMBL16193116 0.86 IRAK4 (0.49) IRAK4ALDH1A1NAMPTSMN1; SMN2LMNA
SCHEMBL14896942 0.85 IRAK4 (0.49) IRAK4ALDH1A1NAMPTMAPTLMNA
SCHEMBL14896714 0.85 CLK2 (0.50) IRAK4ALDH1A1NAMPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885ALDH1A1 1480/4885NAMPT 44/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885ALDH1A1 1480/4885NAMPT 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback